Safety and Feasibility of Adipose Derived Regenerative Cells (ADRCs) in the Treatment of Deep Partial Thickness and Full Thickness Thermal Wounds (RELIEF)
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2018
At a glance
- Drugs ECCS 50 (Primary)
- Indications Burns
- Focus Adverse reactions
- Acronyms RELIEF
- Sponsors Cytori Therapeutics
- 09 Nov 2017 According to a Cytori Therapeutics media release, status changed from planning to recruiting.
- 10 Aug 2017 According to a Cytori Therapeutics media release, enrollment in this trial is expected to begin in Q4 2017.
- 10 Apr 2017 According to a Cytori Therapeutics media release, the company has that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) for a pilot clinical trial to evaluate Cytori Cell Therapy in patients with thermal burn injury.